Extended Data Fig. 3: Agonist treatment study in T cell-depleted mice and B cell-deficient mice. | Nature Immunology

Extended Data Fig. 3: Agonist treatment study in T cell-depleted mice and B cell-deficient mice.

From: Simultaneous STING and lymphotoxin-β receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity

Extended Data Fig. 3

a, Treatment schedule for subcutaneous KPC tumors. CD4+ and/or CD8+ T cells were deleted individually or together by i.p. injection of anti-CD4 and/or CD8 IgG (200 μg) every 4 days, starting from one or two days before tumor inoculation as indicated. Isotype IgG2b was injected for the no-depletion control group. b, T cell depletion was confirmed by FACS analysis of peripheral blood lymphocytes. Rat anti-mouse CD4 (clone: GK1.5) and rat anti-mouse CD8α (clone: 2.43) were used to deplete CD4+ and CD8+ T cells, respectively. Rat IgG2b was used as an isotype control (clone: LTF-2). c, Flow cytometry analyses of spleen and peripheral blood leukocytes show the absence of CD19+ B cells in CD79a knockout mice.

Back to article page